PTGXProtagonist Therapeutics Inc
$97.38
$5.41
(5.26%)
Closed $97.38
$1.93
(1.98%)
After Hours
EarningsAug 6
Mkt Cap$6.26B
Vol887,396.00
Fundamentals
Mkt Cap
$6.26B
Volume
-
52W High
$107.84
52W Low
$49.38
PE Ratio
-53.99
Avg. Volume
519,070.92
EPS (Annual)
-$2.05
Rev/Employee
$348,606.06
Earnings
Aug 06
J&J Stock Gains Nearly 12% Year to Date: Buy, Sell or Hold Now?
JNJ is up nearly 12% YTD as strong oncology drug growth, MedTech demand and pipeline advances help offset Stelara patent-loss pressure.
Zacks
J&J & Pfizer Face Patent Risks: Which Stock Looks Better Positioned?
JNJ's diversified pharma and MedTech growth, pipeline progress and stronger 2026 outlook give it an edge over PFE.
Zacks
J&J's Pipeline Progress & New Drugs Promise Stronger Long-Term Growth
J&J's expanding pipeline, new drug approvals and rising sales from cancer medicines are expected to fuel growth.
Zacks
Tremfya, Icotyde Lead J&J's Post-Stelara Immunology Strategy
JNJ bets on Tremfya and newly approved Icotyde to drive immunology growth as Stelara faces biosimilar pressure.
Zacks
Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Expected to Rise, Wedbush Analyst Says
Wedbush upped their target price on shares of Protagonist Therapeutics from $112.00 to $118.00 and gave the stock an 'outperform' rating in a research report on Wednesday...
MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Posts Earnings Results, Beats Expectations By $0.70 EPS
Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported $0.05 earnings per share for the quarter, topping analysts' consensus estimates of ($0.65) by $0.70. The company had revenue of $56.37 million for the quarter, compared to...
MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Rating of "Moderate Buy" from Analysts
Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) has received an average recommendation of "Moderate Buy" from the fifteen ratings firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a ho...
MarketBeat
331,164 Shares in Protagonist Therapeutics, Inc. $PTGX Bought by Jennison Associates LLC
Jennison Associates LLC bought a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 331,164 shares of the company's stock, v...
MarketBeat
M&T Bank Corp Acquires New Holdings in Protagonist Therapeutics, Inc. $PTGX
M&T Bank Corp acquired a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 11,207 shares of the company's stock, valued at approximately $979,000. Other large investors ha...
MarketBeat
Pictet Asset Management Holding SA Has $46.26 Million Stock Position in Protagonist Therapeutics, Inc. $PTGX
Pictet Asset Management Holding SA lessened its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 35.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 529,631 shares o...
MarketBeat
<
1
2
...
>